Roche receives USFDA emergency use authorization for new test to measure the level of SARS-CoV-2 antibodies

▴ Roche receives USFDA emergency use authorization for new test to measure the level of SARS-CoV-2 antibodies
This test may help identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19

Roche recently announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus. The EUA in the United States follows the launch of the Elecsys Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark announced on 18 September.

The new test targets antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that enables the virus to bind to a host cell receptor, which is required for the virus to enter the host cell. Many current candidate vaccines aim to induce an antibody response against the SARS-CoV-2 spike protein. Tests that quantify antibodies to the spike protein could be used to measure the level of that response and track that measurement over time. The test provides a numerical result describing the concentration of antibodies from 0.40-250 U/mL as well as a qualitative result.

“Since the start of this pandemic, our focus has been to bring effective diagnostic testing solutions to the fight against COVID-19,” said Thomas Schinecker, CEO of Roche Diagnostics. “Antibody tests like these will play a critical role in measuring a person’s vaccine-induced immune response”.

In addition to its role in helping to measure a patient’s immune response, the test may help guide the allocation of plasma donations from recovered COVID-19 patients to current patients by identifying donors that have antibodies to SARS-CoV-2 virus. Convalescent plasma therapy is an investigational procedure that separates and removes the plasma from a patient’s blood. This plasma is then replaced with plasma from a donor to give the ill patient antibodies to help fight the virus.

The laboratory-based Elecsys Anti-SARS-CoV-2 S test runs on Roche’s widely available cobas e analyzers and is the latest addition to Roche’s growing diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care. Currently, this portfolio includes molecular, serology and digital solutions that help healthcare professionals diagnose COVID-19 and provide optimal patient care during the initial stages of infection and the recovery phase, as well as following the resolution of infection.

Tags : #Roche #LatestNewsonRoche3rdDec #LatestPharmaNews3rdDec #LatestUSFDAApproval3rdDec #LatestCOVIDNews3rdDec #LatestNewsonCOVIDTreatment3rdDec #ConvalescentPlasmaTherapy #SpikeProtein

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024
Why the World Trusts Indian Pharmaceuticals for Life-Saving SolutionsDecember 20, 2024
International Tsunami Conference Concludes at AmritapuriDecember 20, 2024
Prestige Marks 75 Years of Revolutionizing Home Cooking with Iconic Innovative ProductsDecember 20, 2024
Revolutionizing Education: Online Learning Platforms Transforming Study Materials for Board and Competitive ExamsDecember 19, 2024
Why Your Blood Pressure Reading Might Be a Lie and How to Fix ItDecember 19, 2024
Vaccines, Cards, and Digital Records: How India is Fighting Healthcare InequalityDecember 19, 2024
Bridging Borders: Sri Lanka’s President Explores India’s Healthcare and HeritageDecember 19, 2024
Jeevan Jyoti Project Brings Eye Care to Alwar's Rural CommunitiesDecember 19, 2024